Endocrine Adverse Events Related to Anticancer Drugs
Conditions
Interventions
Case series:NA
Sponsors
Shanghai Fourth People's Hospital affiliated to Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female 18 years of age or older; 2. Histologically or cytologically confirmed diagnosis of solid tumors, including but not limited to lung cancer, gastric cancer, head and neck squamous cell carcinoma, esophageal cancer, and other solid tumors, who are receiving antineoplastic drug therapy such as chemotherapy, targeted therapy, immune checkpoint inhibitors, or novel therapeutic agents (including but not limited to monoclonal or bispecific antibodies targeting immune or angiogenic pathways, and antibody–drug conjugates [ADCs]). 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 3; 4. Provision to sign and date the informed consent, and stated willingness to comply with all study procedures and remain available for the duration of the study.
Exclusion criteria
Exclusion criteria: 1. Known human immunodeficiency virus (HIV) infection or active tuberculosis; 2. Known pregnancy or lactation; 3. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of endocrine adverse events related to anticancer drugs;Time to onset of endocrine adverse events related to anticancer drugs;Severity of endocrine adverse events related to anticancer drugs;Risk factors of endocrine adverse events related to anticancer drugs;Disease-Free Survival (DFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Progression-Free Survival (PFS);Objective Response Rate (ORR);Disease Control Rate (DCR);Duration of Response (DoR); | — |
Countries
China
Contacts
Public ContactCongrong Wang
Shanghai Fourth People's Hospital affiliated to Tongji University
Outcome results
None listed